Antithrombotic use after intracerebral haemorrhage |
Use antiplatelets if there is a strong indication (eg, related to ischaemic hear disease, ischaemic stroke or TIA). Whether to start or avoid OAC after ICH in patients with AF remains uncertain. If restarting OAC, reinitiating with an NOAC at 7–8 weeks appears sensible. The role of LAAO remains uncertain in ICH survivors with AF. Recruitment to ongoing RCTs of OAC and LAAO is recommended.
|
Antithrombotic use in patients with CMBs |
Use antiplatelets or OAC if indicated. Use the MICON-ICH score to determine the risk of future intracranial bleeding. Avoid OAC in patients with CMBs in the context of ICH and probable CAA. Careful management of modifiable bleeding risk factors.
|
Antithrombotic use in patients with indications for antiplatelets and OAC |
Use combination therapy in patients with recent ACS. Avoid combination therapy in patients with coronary or peripheral artery disease without associated vascular events in the last 12 months. Pay attention to modifiable bleeding risk factors if combination therapy used. Consider early cessation of combination therapy in patients at high bleeding risk (eg, HASBLED >3). Novel combination strategies (eg, low-dose NOAC and antiplatelet) should be investigated.
|
Timing of anticoagulation after AF-associated ischaemic stroke |
Optimal timing remains to be determined for all degrees of stroke severity: offer enrolment to RCT if available. If no RCT available, early anticoagulation (within 5 days) with an NOAC is probably safe in patients with minor stroke. Delay anticoagulation by 5–14 days in patients with moderate-severe stroke.
|
Antithrombotic ‘failure’ |
Review medication dosing, compliance, and interactions. Investigate for competing aetiology. Consider short-term dual antiplatelet therapy in patients with recurrent non-cardioembolic stroke despite antiplatelets. Switch of anticoagulant type in patients with AF does not appear to reduce recurrence risk.
|
‘Silent’ cerebral small vessel disease |
Routine antiplatelet use not recommended for asymptomatic cerebral small vessel disease. Consider antiplatelets in patients with asymptomatic territorial infarcts of likely atherosclerotic or atheroembolic cause.
|